Humacyte Stock Odds of Future Stock Price Finishing Under 1.74
| HUMAW Stock | USD 1.85 0.02 1.09% |
Humacyte |
Humacyte Target Price Odds to finish below 1.74
The tendency of Humacyte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 1.74 or more in 90 days |
| 1.85 | 90 days | 1.74 | about 44.19 |
Based on a normal probability distribution, the odds of Humacyte to drop to $ 1.74 or more in 90 days from now is about 44.19 (This Humacyte probability density function shows the probability of Humacyte Stock to fall within a particular range of prices over 90 days) . Probability of Humacyte price to stay between $ 1.74 and its current price of $1.85 at the end of the 90-day period is about 20.52 .
Assuming the 90 days horizon Humacyte has a beta of 0.31. This usually indicates as returns on the market go up, Humacyte average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Humacyte will be expected to be much smaller as well. Additionally Humacyte has an alpha of 0.4708, implying that it can generate a 0.47 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Humacyte Price Density |
| Price |
Predictive Modules for Humacyte
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Humacyte. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Humacyte Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Humacyte is not an exception. The market had few large corrections towards the Humacyte's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Humacyte, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Humacyte within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.47 | |
β | Beta against Dow Jones | 0.31 | |
σ | Overall volatility | 0.21 | |
Ir | Information ratio | 0.05 |
Humacyte Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Humacyte for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Humacyte can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Humacyte had very high historical volatility over the last 90 days | |
| Humacyte may become a speculative penny stock | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Humacyte generates negative cash flow from operations | |
| Latest headline from news.google.com: Humacyte Shares Surge 38 percent on FDA Approval of Symvess - MarketWatch |
Humacyte Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Humacyte Stock often depends not only on the future outlook of the current and potential Humacyte's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Humacyte's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 103.4 M | |
| Cash And Short Term Investments | 80.4 M |
Humacyte Technical Analysis
Humacyte's future price can be derived by breaking down and analyzing its technical indicators over time. Humacyte Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Humacyte. In general, you should focus on analyzing Humacyte Stock price patterns and their correlations with different microeconomic environments and drivers.
Humacyte Predictive Forecast Models
Humacyte's time-series forecasting models is one of many Humacyte's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Humacyte's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Humacyte
Checking the ongoing alerts about Humacyte for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Humacyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Humacyte had very high historical volatility over the last 90 days | |
| Humacyte may become a speculative penny stock | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Humacyte generates negative cash flow from operations | |
| Latest headline from news.google.com: Humacyte Shares Surge 38 percent on FDA Approval of Symvess - MarketWatch |
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.